CTLA4 and melanoma: Then, the immunotherapy response and survival analysis with three cancer transcriptomic cohorts receiving ICB, including melanoma (Fig. S13C, GSE78220, n = 28, with anti-PD1; Fig. S13D, Van-allen, n = 42, with anti-CTLA4) and metastatic urothelial cancer (Fig. S13E, IMvigor210, n = 348, with anti-PD-L1) demonstrated that the SASP Score may efficiently stratify the patients’ response to anti-PD1 (GSE78220) instead of other two ICB strategy [9, 54].